Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Secondcell Bio has developed and commercialized Chromovert®, a proprietary technology for rapid, stable engineering of mammalian cell lines expressing one or more genes of interest. The company’s platform enables accelerated drug discovery and has been used to develop a leading non-addictive pain drug candidate that received FDA fast-track designation. The company claims successful commercial validation across diverse fields and is expanding operations internationally, including joint ventures in the UAE[1][2][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Secondcell Bio.